Acute respiratory infection due to *Mycoplasma pneumoniae*: current status of diagnostic methods

K. Loens • H. Goossens • M. Ieven

Received: 16 March 2010 / Accepted: 18 May 2010 / Published online: 6 June 2010
© Springer-Verlag 2010

Abstract Because of the absence of well-standardized both in-house and FDA-approved commercially available diagnostic tests, the reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* remains difficult. In addition, no formal external quality assessment schemes which would allow to conclude about the performance of *M. pneumoniae* diagnostic tests exist. In this review, the current state of knowledge of *M. pneumoniae*-associated respiratory infections in the context of epidemiological studies published during the past 5 years is discussed, with particular emphasis on the diagnostic strategies used and their impact on results. The role of *M. pneumoniae* as a cause of respiratory tract infections (RTIs) differs from study to study due to geographical and epidemiological differences, as well as to the application of different diagnostic techniques and criteria used.

Introduction

In 2003, we already stated that proper validation and standardization of nucleic acid amplification techniques (NAATs) are often lacking, and that the different methods used must be compared in order to define the most sensitive and specific tests [1]. This is similar for existing serological tests and other new diagnostic tests as well. Studies comparing different methods still remain to be undertaken and will be critically important for the development of a standardized test for clinical laboratories.

*Mycoplasma pneumoniae* belongs to the class of the Mollicutes and has been associated with a wide variety of acute and chronic diseases. Respiratory tract infections (RTIs) with *M. pneumoniae* occur worldwide and in all age groups.

Serological methods, in particular, such as the complement fixation test (CFT) and enzyme immunoassays (EIAs), are most widely used to diagnose an *M. pneumoniae* infection. The application of polymerase chain reaction (PCR) is more and more often accepted as a rapid diagnostic test, since culture is too slow and too insensitive to be therapeutically relevant. Only a few of the currently available NAATs have been extensively validated against culture, which remains the reference standard, despite its low sensitivity and variable yield, depending on the specimens tested and the isolation protocols used. The sensitivity of NAATs is almost always superior to that of the traditional procedures, and they are more and more often considered as the “new gold standard”. However, different studies have used not only different diagnostic tools or combinations thereof, but also different diagnostic criteria for making a diagnosis of an infection, thereby, making comparison between studies difficult. Most importantly, the lack of standardization has resulted in a wide variation of interlaboratory test performance, even when using the same test and criteria [2]. In an effort to standardize diagnostic assays for *C. pneumoniae*, recommendations have been published by the US Centers for Disease Control and Prevention (CDC) and the Canadian Laboratory Centre for Disease Control in 2001 [3]. However, no such recommendations exist for standardizing the diagnostic approach for *M. pneumoniae*. The epidemi-
Epidemiology of respiratory infection due to *M. pneumoniae*

Varying with the population studied and diagnostic methods used, in studies published during the 1990s, in 6 to >30% of lower respiratory tract infections (LRTIs), an association was found with *M. pneumoniae* [4–6]. Over 50 additional studies have been published about *M. pneumoniae*-associated LRTI since 2003. Data from selected studies chosen to represent different populations from around the world are summarized in Tables 1 and 2. As shown in these tables, the proportion of LRTI in children and adults, including community-acquired pneumonia, associated with *M. pneumoniae* infection during the past 5 years has ranged from 0 to 66.7% [7, 8], varying with age and the geographic location of the population examined and the diagnostic methods used. In a lot of studies, the diagnosis of *M. pneumoniae* was based on serology alone [7, 9–11]; some used a PCR assay alone [8, 12, 13] or at least one serological test and a PCR assay [14–20]. Only a limited number of studies used culture in combination with a serological test and/or PCR assay [21–25] and three studies applied two different PCR assays [26–28]. Furthermore, there was a high degree of heterogeneity from study to study in the serological methods and criteria used. These are not necessarily interchangeable. In some studies, no data were presented on the type of assay and the criteria used, thereby, making it difficult, if not impossible, to compare results from one study to another.

One example is a prospective study of the incidence and etiology of community-acquired pneumonia in hospitalized adult patients [29] published in 1999. The researchers used serological methods and PCR for the diagnosis of an *M. pneumoniae* infection. The following serological criteria were used: a 4-fold rise or seroconversion in IgG- and/or an IgM-positive titer for *M. pneumoniae*. Fourteen percent of the patients were thought to have serological evidence of *M. pneumoniae* infection, but no information was provided on the serological method used. Furthermore, the study had no control subjects, and because of their absence, the significance of the reported seroprevalence of the patient group cannot be known. Background rates of seropositivity can be very high in some adult populations, ranging from 36 to 93% for IgG and ranging from 0 to 51% for IgM, depending on the assay used [30].

Another example is the study of Oosterheert et al. [8]. In a randomized controlled trial, nasopharyngeal and oropharyngeal swab specimens from patients admitted for antibiotic treatment of LRTIs were evaluated by means of real-time PCR for respiratory viruses and atypical pathogens, as well as by conventional diagnostic procedures for virus detection. No details on the real-time PCR were given, although no *M. pneumoniae*-positive patient results were identified. No other methods were used in this study to confirm the negative results.

In general, in more recent studies using PCR assays, lower rates of *M. pneumoniae*-associated LRTI have been reported than in studies using serological testing (Tables 1 and 2). During a community outbreak of *M. pneumoniae*, Nilsson et al. [28] compared semi-nested and real-time PCR of oropharyngeal swabs with serology for the diagnosis of *M. pneumoniae* infections at different time points after the onset of disease. *M. pneumoniae* was diagnosed in 48/164 patients with a respiratory tract infection. Forty-five (29%) were PCR-positive, whereas a significant rise in IgG titer or IgM antibodies was detected in 44/154 (27%) subjects. Although the authors found that persistence of *M. pneumoniae* DNA in the throat was common and could be present for up to 7 weeks after the onset of disease, they concluded that PCR was superior to serology for the diagnosis of an *M. pneumoniae* infection during the early phase of infection. When examining 73 children with RTIs for *M. pneumoniae* by real-time PCR and two serological assays (a passive agglutination test and the ImmunoCard assay), Otomo et al. [31] confirmed the results of Nilsson et al. [28]. They found sensitivities of 100% and 33.3% and specificities of 100% and 82.1% for PCR and the ImmunoCard assay, respectively. According to the authors, real-time PCR or a related molecular assay is suitable for rapid diagnosis as a first screening test. These data confirmed the lack of correlation of serological methods with culture and/or PCR assays reported in earlier studies [1].

The epidemiological data emerging from pediatric studies have revealed similar inconsistencies of the methods and criteria used to make a diagnosis of an acute *M. pneumoniae* infection (Table 2). Examples include the use of single IgG titers by some studies (Table 2). A more specific example is a small uncontrolled pediatric study in Turkey [17] collecting nasopharyngeal samples for the PCR detection of *M. pneumoniae* DNA and blood for serology on the first admission to the hospital. However, they did not specify the PCR test applied, and although blood was only collected once (on hospital admission), serological diagnosis was made according to the materials and methods section by demonstrating an increment of IgM greater than 1/10 and a 4-fold increase in IgG with enzyme-linked immunosorbent assay (ELISA). No positive case definition
Table 1 Summary of studies of respiratory infections due to *Mycoplasma pneumoniae* in adults published since 2003

| Reference | Location          | Subject age (years) | No. of subjects tested | Diagnostic method(s)                                    | No. (%) of subjects infected with *M. pneumoniae* | Comments | Methodological problem(s) |  |
|-----------|-------------------|---------------------|------------------------|--------------------------------------------------------|-----------------------------------------------|----------|--------------------------|---|
| [16] 2004 | The Netherlands    | 1–88                | 159                    | P1 gene-based PCR, particle agglutination and ELISA     | 19 (11.9)                                     | 7 PCR-positive, all also positive in at least one serological test, 2-fold titer increase in IgG was defined as positive | D        |
| [7] 2004  | Trinidad and Tobago | >2                  | 132                    | IgM and IgG EIA on acute phase serum                     | 88 (66.7)                                     | 36/88 IgM-positive                                   | B        |
| [14] 2005 | France             | ≥18                 | 3,198                  | P1-based PCR, Ag detection by EIA                        | 109 (3.6)                                     | 114 PCR-positive, Ag detection test had very low sensitivity and the results were not mentioned as such 8 positive by IFI (of which 4 by IFI alone), 7 PCR-positive (of which 3 only by PCR) | E        |
| [27] 2005 | Chile              | 60–96               | 84                     | P1 gene-based PCR, 16S rRNA gene-based PCR, IgM and IgG indirect IF | 11 (13.1)                                     | 8 positive by IFI (of which 4 by IFI alone), 7 PCR-positive (of which 3 only by PCR) | ...      |
| [8] 2005  | The Netherlands    | ≥18                 | 107                    | PCR                                                    | 0 (0)                                         | PCR not described                                  | A        |
| [26] 2006 | UK                 | ≥18                 | 80 patients 49 controls| P1 gene-based PCR, 16S rRNA-based PCR                    | 1 (1.3)                                       | 1 PCR-positive patient                             | ...      |
| [18] 2006 | Denmark            | 18–96               | 235 patients 113 controls| P1 gene-based PCR and CFT                               | 14 (5.5)                                      | 13 positive patients, 1 positive control Proportion of positive results by each test not specified | ...      |
| [25] 2007 | India              | ≥18                 | 100                    | Culture, IgM ELISA, cold agglutination test on acute-phase sera | 31 (31)                                       | 31 positive by culture, 21 positive by IgM ELISA, 34 positive by cold agglutination test | ...      |
| [22] 2008 | Belgium            | ≥18                 | 147                    | Mono and MX real-time NASBA, real-time PCR, culture, IgM and IgG EIA | 19 (12.9)                                     | 8 positive by culture, 15 positive by PCR, 19 positive by real-time MX NASBA, 23 by mono real-time NASBA | ...      |
| [19] 2008 | The Netherlands    | ≥18                 | 201                    | PCR, CFT                                              | 8 (4.0)                                       | 7 positive by PCR, 8 positive by serology PCR not specified | A        |
| [23] 2008 | Japan              | 16–>80              | NS                     | Culture, IgM, and IgG serology                          | 210                                            | 210 IgG *M. pneumoniae*-positive, 38 culture-positive | ...      |

*A: no information provided about the PCR and/or serological assay used; B: single IgG titer used as part of the criteria used to define an acute infection; C: EIA used as the only serodiagnostic tool; D: serological titers vary from those recommended for the diagnosis of acute infections; E: one PCR assay used as the only diagnostic tool; F: (single) IgM titer used as the only serodiagnostic tool in some or all patients Ag: antigen; CFT: complement fixation test; IFI: indirect immunofluorescence; IgA/G/M: immunoglobulin A/G/M; MX: multiplex; NASBA: nucleic acid sequence-based amplification; …: no major methodological problems identified*
Table 2 Summary of studies of respiratory infections due to *M. pneumoniae* in pediatric patients published since 2003

| Reference | Location | Subject age (years) | No. of subjects tested | Diagnostic method(s) | No. (%) of subjects infected with *M. pneumoniae* | Comments | Methodological problem(s) |
|-----------|----------|---------------------|------------------------|----------------------|--------------------------------------------------|----------|-------------------------|
| [21] 2003 Chile 0–14 106 | 16S rRNA gene-based PCR, IgM serology (two tests) on acute serum, culture | 31 (29.2) | 31 positive by IgM, in 28/31 cases, serology was confirmed by PCR, 19 positive by culture | ... |
| [12] 2004 The Netherlands 0–16 168 | P1 gene-based PCR | 4 (2.4) | 18 positive by IgM, 9 PCR-positive | E |
| [15] 2004 Greece 0.5–14 65 | P1 gene-based PCR and IgM serology on acute-phase serum | 18 (27.5) | 68 positive by PCR, 53 culture-positive, 76 serology-positive | F |
| [70] 2004 Japan 0–14 369 | 16S rRNA gene-based PCR, CFT, culture | 69 (18.7) | 27 patients positive with two or more tests, 12 patients positive with only one test | C |
| [9] 2005 Finland 0.3–16 101 | CFT, IgM, and IgA serology | 27 (27) | All positive results were found in patients | E |
| [13] 2005 China 0–5 85 patients 185 controls | ATPase-based PCR | 6 (7.1) | All positive by single IgM determination | F |
| [11] 2005 India 0–16 93 | IgM ELISA on acute-phase serum | 22 (24) | Not clear whether positive in acute, convalescent, or both sera | F |
| [10] 2006 Finland 0–16 220 | 2 IgM EIAs | 11 (5) | 66 PCR-positive, 106 PA titers above 1:40, among PCR-positive patients, 30/36 had a ≥4-fold increase in PA titer, 36/81 positive for IgG, 16/81 positive for IgA, and 54/81 positive for IgM | ... |
| [20] 2006 Japan 0–6 339 | P1 gene-based PCR, passive agglutination, IgM, IgG, and IgA ELISA | 81 (23.9) | 14 culture-positive, ImmunoCard-positive in 39 paired sera and in 14 acute sera, CFT results not mentioned | ... |
| [24] 2007 Japan 0–15 194 | Culture, CFT, rapidtest | 45 (23.2) | 33/203 PCR-positive, 86/284 IgM patients, only in 13 cases positive by both PCR and IgM | ... |
| [17] 2007 Turkey 5–15 284 | PCR, IgM ELISA on acute-phase serum | NS | 6/6 PCR-positive, 5/6 IgG seroconversion/ significant rise, one additional positive by IgG serology, 2/6 ImmunoCard assay-positive, 12 additional patients positive by ImmunoCard assay | ... |
| [31] 2008 Japan 0–15 73 | 16S rRNA gene-based PCR, IgM and IgG serology | 6 (8.2) | ... | ... |

---

* A: no information provided about the PCR and/or serological assay used; B: single IgG titer used as part of the criteria used to define an acute infection; C: EIA used as the only serodiagnostic tool; D: serological titers vary from those recommended for the diagnosis of acute infections; E: one PCR assay used as the only diagnostic tool; F: (single) IgM titer used as the only serodiagnostic tool in some or all patients

Ag: antigen; CFT: complement fixation test; IFI: indirect immunofluorescence; IgA/G/M: Immunoglobulin A/G/M; MX: multiplex; NASBA: nucleic acid sequence-based amplification; NS: not specified; …: no major methodological problems identified
was mentioned either. The authors concluded that serological tests were more sensitive and specific than PCR, since the false-positive ratio for PCR was 16.2%. Another small uncontrolled pediatric study in Dallas, Texas [32], identified *M. pneumoniae* as the cause of infection in 14% of patients with pneumonia. The center applied an ELISA for serological testing and used a 4-fold increase of IgG or single IgM titers of ≥1:10 as evidence of acute infection. However, they did not specify the proportion of positive results by the different antibody classes and no information on the ELISA was presented.

The true role of *M. pneumoniae* in RTIs remains a challenge given the wide variations of data from studies with equally wide variation of and lack of standardized diagnostic methods.

**Serology**

The serologic measurement of specific antibody responses has limited application for an etiologic diagnosis of an *M. pneumoniae* infection because diagnostic results are only available retrospectively.

A great number of antigen preparations have been proposed: whole organisms, protein fractions, glycoprotein fractions, recombinant antigens. Some commercialized assays lack both sensitivity and specificity, emphasizing the need for more validation and quality control [30, 33–35].

The sensitivity of the serological assays depends on whether the first serum sample is collected early or late after the onset of disease and on the availability of paired sera, since for an accurate diagnosis to be made, paired serum samples are required, with a 4-fold rise in titer appearing after three to four weeks after the onset of disease [36]. In practice, however, often, only one serum sample, from the acute-phase of the illness, is available or the two samples are collected within a too short time interval to detect a titer rise. Solitary high IgG titers have no diagnostic meaning for an acute infection, since the moment of the seroconversion is unknown and necessarily took place some time before the illness under observation started. Single high titers, for which a cut-off value has to be determined by a local evaluation, are useful only in prevalence studies among population groups.

Since IgM antibodies appear earlier than IgG antibodies, the detection of IgM in serum is a widely used approach for the early serologic diagnosis of an *M. pneumoniae* infection, especially in children. It should be realized that IgM antibodies are often not produced in children under 6 months of age, in a proportion of primary infections and during reinfections. A single IgM measurement may detect an acute infection with higher sensitivity if the test is performed after at least 7 days following the onset of disease [37]. In some patients, IgM antibodies appear even later [38]. Ozaki et al. [24] found that a single assay using the IgM ImmunoCard (Meridian Biosciences) had a sensitivity of 31.8% for the detection of an acute *M. pneumoniae* infection, which increased to 88.6% when paired sera were analyzed from seropositive children with pneumonia. Furthermore, an elevated IgM may persist for months after the acute infection [39]. IgM tests are usually less sensitive and specific than 4-fold changes in antibody titers between paired specimens separated by several weeks [40].

It has been reported that the detection of IgA-specific antibody seems to be a good indicator of a recent *M. pneumoniae* infection in both children and adults [41–43]. On the other hand, when evaluating the Medac IgM, IgG, and IgA assay on 159 serum samples from 113 patients with acute RTIs, Narita [44] did not find a significant advantage of detecting IgA in children.

Talkington et al. [35] compared eight commercial EIAs (two single-use EIAs and six plate-type EIAs) for the detection of specific IgM/IgG antibodies, using paired serum samples from 51 patients with a confirmed *M. pneumoniae* infection and a positive complement fixation test (CFT). The results from acute-phase sera ranged from 14% ImmunoWELL IgM-positive to 45% positive by Zeus IgG EIA. When both the acute-phase and convalescent phase serum samples were analyzed, positive results ranged from 39% by the ImmunoWELL IgM assay to 88% positive by the Remel IgG-IgM EIA. In their study, the single-use EIAs proved to be more reliable than the plate-type EIAs. Beersma et al. [30] evaluated the sensitivity and specificity of 12 assays for the detection of *M. pneumoniae* IgM and IgG, as well as the CFT. Some of the assays had a low sensitivity (Novum and ImmunoCard IgM), while the best performances in terms of sensitivity and specificity were recorded for ANILab systems (77 and 92%, respectively) and the CFT (65 and 97%, respectively). Petitjean et al. [34] found similar IgM sensitivities with four *M. pneumoniae* tests in children: between 89 and 92%, but wide variations in adults: Platelab and BMD 16%, Biotest 50% and Sorin 58%. The specificities of the tests were 100, 90, 65, and 25% respectively. The latter two IgM tests cannot, thus, be used for diagnosis. The sensitivities of the IgG tests in children varied between 52 and 78%. The sensitivities for the IgG tests in adults were comparable: between 89 and 92%. When comparing four IgM-, IgG-, and IgA-specific EIAs in sera from 504 blood donors and 102 patients with infections not caused by *M. pneumoniae*, Csángó et al. [45] reported the detection frequencies of IgM in blood donors varying between 2.8 and 16% and in patients between 9.8 and 42.2%. IgA was detected in 22.8 to 68.5% of blood donor sera and in 53.8 to 100% of
patients, illustrating again that the use of some serological kits may lead to a serious overdiagnosis of *M. pneumoniae* infections. Finally, Nir-Paz et al. [33] compared eight commercially available tests for *M. pneumoniae* using 204 single sera from healthy individuals. The study showed that age was associated with test positivity in healthy individuals, with the IgM peaking at primary/secondary school age, and declining thereafter, while IgG rose progressively into adulthood. The high IgM positivity in these age groups casts doubt on the suggestion that combining IgM tests with amplification-based tests in the pediatric population might be of benefit [6, 46, 47]. Inter-assay agreement was poor. The study confirmed that single serum serology is unsuitable for the diagnosis of *M. pneumoniae* infection, and that commercially available tests need further improvement.

In conclusion, serologic tests can never offer an early diagnosis and are, therefore, an epidemiological than a diagnostic tool. The clinical significance of a serologic test, for both IgM and IgG, should be defined by studies of patients with a documented infection and for whom detailed information concerning the time lapses between the onset of disease and the collection of the serum specimens are known.

**Culture**

*M. pneumoniae* was first recovered on a medium devised by Hayflick in which PPLO agar [48] was supplemented with a fresh yeast extract preparation of Edward [49] and 20% horse serum. However, *M. pneumoniae* grows slowly, so cultures may require up to 6 weeks to become positive. Although the culture of *M. pneumoniae* is still considered to be the gold standard, it is seldomly performed as a diagnostic test.

Culture is, and will remain, essential for further biological and molecular characterization of clinical isolates (including antibiotic resistance studies); however, its use as a routine diagnostic tool is suboptimal.

**PCR**

Over the last 20 years, NAATs have become a major tool for the detection of micro-organisms, for diagnostic testing, and for research purposes in the field of infectious diseases. NAATs offer significant sensitivity and speed compared to culture and do not require the presence of viable organisms. Diagnostic testing for micro-organisms based on NAATs has become increasingly complex and the field is changing and expanding rapidly. Thus, an NAAT established 10 years ago and designed with the best information and knowledge available at that time may not necessarily be state-of-the-art today.

Validated commercially available FDA-cleared assays exist only for a limited number of organisms and not for the detection of *M. pneumoniae* in respiratory or other specimens. There are also a number of so-called analyte-specific reagents commercially available. Besides these standardized kits, the use of NAATs for research purposes kits and in-house developed NAATs has expanded tremendously. The assays range from those that are well validated to those that are not. Carefully reading many of these publications reveals that, often, little or no information is provided on the validation of the NAATs applied. Yet, these assays are frequently used and cited in the literature.

At the time of the 2003 minireview [1], there were 34 published in-house NAATs for the detection of *M. pneumoniae* DNA or RNA. However, validation was primarily analytical; none of these assays were extensively evaluated using clinical specimens from well-defined patient populations from a wide geographic area. Since then, an additional 27 assays have been described (Tables 3 and 4). There is a great variation of the methods used from study to study, including variability of target (P1 gene, 16S rRNA, ATPase gene, parE gene, tuf gene; monoplex versus multiplex targets) and of NAAT (conventional, nested, and real-time; RNA vs. DNA targets; and PCR and nucleic acid sequence-based amplification technologies) and detection formats (agarose gel electrophoresis, SYBR green, TaqMan probe, hybridization probes, molecular beacons, and microchip electrophoresis). Furthermore, there is no consensus on the optimal respiratory specimen to be used for *M. pneumoniae* detection by nucleic acid amplification tests and culture. Different specimens have been used, such as sputum, nasopharyngeal, or oropharyngeal swabs or washes; bronchoalveolar lavage; or pleural fluid. In a review on optimal sampling for the detection of respiratory pathogens, Loens et al. concluded that, if sputum is available, it might be the best specimen for *M. pneumoniae* detection by culture and NAATs. A nasopharyngeal swab, nasopharyngeal aspirate, or oropharyngeal swab might be the second best option for analysis by NAATs [50].

Interstudy variation is related to the reference diagnostic assay with which the new assay is compared (a serological test, culture, or a pre-existing PCR assay). Due to the lack of conformity between different studies, it is very difficult to compare the data from study to study.

Winchell et al. [51] evaluated three real-time PCR assays targeting the ATPase gene and newly described CARDS toxin genes during an *M. pneumoniae* outbreak. A total of 54 respiratory specimens from patients (*n*=35) and controls (*n*=19) were tested in triplicate with each PCR assay. The assay targeting the CARDS toxin gene proved to be the most sensitive (lower ct-values) in identifying positive
| Reference | Assay type | Detection format | Target gene (bp) | PCR assay used as a comparator for the new assay | Non-PCR comparator test | Specimens tested for the validation of sensitivity and/or specificity |
|-----------|------------|------------------|-----------------|-----------------------------------------------|------------------------|---------------------------------------------------------------------|
| 2003 [71] | PCR        | Molecular beacons | P1 gene (151)   | [72, 73]                                      | Serology               | Various bacterial species, DNA dilutions, clinical specimens         |
| 2004 [70] | PCR        | Agarose gel electrophoresis | 16S rRNA gene (225) | ND | Culture, serology | M. pneumoniae dilution series                                      |
| 2004 [74] | Broad-range PCR | Microarray | parE gene (±300) | ND | ND | Various bacterial species, DNA dilutions, clinical specimens        |
| 2004 [60] | Nested PCR | Reverse line blot hybridization | 16S-23S rRNA spacer (94) | ND | ND | 21 Mollicute reference strains, 92 contaminated cell cultures, 14 M. pneumoniae-positive NPA's, 6 M. pneumoniae-negative specimens Pathogens targeted: M. arginini, M. fermentans, M. hyorhinis, M. orale, Acholeplasma laidlawii, M. pneumoniae, M. hominis, M. genitalium, Ureaplasma parvum, U. urealyticum |
| 2005 [75] | PCR        | Real-time         | 16S RNA gene (NS) | ND | Culture | Spiked sputa and BALs, clinical specimens with known M. pneumoniae status by culture |
| 2005 [76] | LAMP       | Turbidimeter      | P1 gene (NS)     | [77] | ND | Various bacterial species, DNA dilutions, clinical specimens        |
| 2006 [78] | PCR        | Molecular beacon  | 16S rRNA gene (225) | ND | Culture, serology | Various bacterial species, bacterial dilution series, clinical specimens |
| 2006 [79] | PCR        | Real-time         | P1 gene (141)    | ND | Culture, serology | Various bacterial strains, dilutions of cloned DNA, clinical specimens with known M. pneumoniae status by culture and serology |
| 2007 [80] | PCR        | Scorpion probe    | P1 gene (72)     | [81, 82] | Serology | Various bacterial strains, dilutions of M. pneumoniae DNA, clinical specimens with unknown status |
| 2007 [83] | PCR        | Real-time         | repMp1 in P1 (184) | P1 gene-based PCR (177 bp) | ND | Various bacterial species, dilutions of plasmids containing target sequence, clinical specimens with known M. pneumoniae status by PCR |
| 2008 [51] | PCR        | Real-time         | CARDS toxingene (73) ATPase gene(68) | ND | ND | Various bacterial species, bacterial dilution series, clinical specimens from an outbreak |
| 2009 [59] | Broad-range PCR | Real-time | CARDox gene(160) | VenoGeM-DI Mycoplasma detection kit, MycoSensor QPCR Assay kit | ND | 32 Mollicute species, various other bacterial species, cell culture supernatants, clinical specimens (80sputa, 5 throat swabs) |

A-test: passive agglutination-test; LAMP: loop-mediated isothermal amplification; ND: not done; MycoSensor QPCR Assay (Stratagene, LaJolla, CA, USA); VenoGeM-DI Mycoplasma detection kit (Minerva Biolabs GmbH, Berlin, Germany)
Table 4  Summary of recent multiplex PCR assays for the detection of *M. pneumoniae* published since 2003 and previously validated assays used as comparators

| Reference | Assay type | Detection format | Target gene (bp) | PCR assay used as a comparator for the new assay | Non-PCR comparator test | Specimens tested for the validation of sensitivity and/or specificity |
|-----------|------------|------------------|------------------|-------------------------------------------------|-------------------------|------------------------------------------------------------------|
| 2004 [84] | MX-PCR     | Microchip electrophoresis | 16S rRNA gene(88) | Mono-assay                                      | Serology                | *M. pneumoniae* dilution series, various bacterial species, clinical specimens |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *Chlamydophila pneumoniae*, and *Legionella pneumophila* |
|           |            |                   |                  |                                                 |                         | DNA dilutions, *M. pneumoniae*-negative clinical specimens |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: influenza A and B, RSV A and B, metapneumovirus, SARS, coronavirus OC43 and 229E, parainfluenza 1-3, *C. pneumoniae*, *M. pneumoniae*, *L. pneumophila*, enterovirus, adenovirus |
| 2005 [85] | Mass Tag MX-PCR | Masscode Tag | NS               | ND                                              | ND                      | Various bacterial species, bacterial dilutions, clinical specimens with known status, clinical specimens with unknown status |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *C. pneumoniae*, *M. pneumoniae*, *Legionella* spp. |
|           | [57]       | Hybridization     | P1 gene (298)    | [86]                                            | Serology                | Various bacterial species, bacterial dilutions, clinical specimens with known status, clinical specimens with unknown status |
|           | MX-PCR     |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, Bordetella pertussis |
| 2005 [56] | MX-PCR     | Real-time         | 16S rRNA gene    | NS                                              | ND                      | Various bacterial species, dilutions of recombinant DNA, dilutions of organisms, spiked BALs |
|           | Pneumoplex |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, *L. micdadei*, Bordetella pertussis |
|           | 2005 [87]  | MX-PCR            | Agarose gel electrophoresis | P1 gene (360) | [72]                                              | ND                       | Various bacterial specimens, dilutions of organisms, clinical specimens with known *M. pneumoniae* status by PCR |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, B. pertussis |
| 2005 [88] | MX-PCR     | Agarose gel electrophoresis | P1 gene (483)    | ND                                              | ND                      | Various bacterial species, serial dilutions of DNA, clinical respiratory specimens |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *Streptococcus pneumoniae*, *Haemophilus influenzae*, *M. pneumoniae*, *C. pneumoniae* |
| 2007 [89] | MX-PCR     | Agarose gel electrophoresis | P1 gene (225)    | *M. pneumoniae* OligoDetect PCR kit, P1-based in-house PCR | ND                      | Extracts from samples known to be positive for some common respiratory bacterial pathogens, clinical specimens from children with RTIs |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *C. pneumoniae*, B. pertussis, B. parapertussis |
| 2007 [90] | Nested MX-PCR | Agarose gel electrophoresis | P1 gene (343, 160) | ND                                              | ND                      | DNA dilutions, clinical specimens |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, adenovirus |
| 2007 [55] | MX-PCR     | Resequencing microarray | NS               | ND                                              | ND                      | Various bacterial species, *M. pneumoniae* cells, DNA dilutions, archived throat swabs |
|           |            |                   |                  |                                                 |                         | Pathogens targeted: adenovirus, *Bacillus anthracis*, *C. pneumoniae*, influenza virus A and B, *Francisella tularensis*, coronavirus 229 E and OC43, rhinovirus, Lassa virus, *M. pneumoniae*, parainfluenza virus 1, 3, RSV A and B, *S. pneumoniae*, *S. pyogenes*, vaccinia virus, *Yersinia pestis*, Ebola virus, Variola major virus |
| Year | Method | Assay Format | Gene | Assay Used as Comparator | Targets |
|------|--------|--------------|------|--------------------------|---------|
| 2007 | MX-PCR | Microarray with electrochemical detection | dnaK gene (654), pdhA gene (284), tuf gene (604) | ND | Various bacterial and viral species, dilution series. Pathogens targeted: B. pertussis, S. pyogenes, C. pneumoniae, M. pneumoniae, adenovirus, coronavirus OC43, 229E, and HK, influenza A and B, parainfluenza types 1, 2, and 3, RSV |
| 2008 | MX-PCR | Luminex technology | ATPase (NS) | ND | M. pneumoniae type I and II, >110 strains of other bacterial species found in the respiratory tract or related spp., 10-fold serial DNA dilutions, 49 NPS with known M. pneumoniae status by PCR. Pathogens targeted: S. pneumoniae, Neisseria meningitidis, H. influenzae, L. pneumophila, M. pneumoniae, C. pneumoniae |
| 2008 | MX-PCR | Molecular beacons | P1 gene (158) | ND | Reference strains of common bacterial respiratory pathogens or related species, serial dilutions of DNA, spiked samples, samples with known status by PCR. Pathogens targeted: M. pneumoniae and C. pneumoniae |
| 2008 | MX NASBA | Molecular beacons | 16S rRNA | Culture, serology | Various bacterial species, bacterial dilutions, dilutions of wild-type M. pneumoniae 16S rRNA generated in vitro, spiked specimens, specimens with known status by PCR. Pathogens targeted: M. pneumoniae, C. pneumoniae, Legionella spp. |
| 2008 | MX-PCR | Reverse line blot hybridization | 16S-23S rRNA spacer (93) | ND | 12 reference strains and 63 clinical isolates of common bacterial respiratory pathogens, 10-fold serial DNA dilutions, 100 NPAs from children with CAP. Pathogens targeted: Staphylococcus aureus, S. pneumoniae, S. pyogenes, Moraxella catarrhalis, H. influenzae, B. pertussis, Klebsiella pneumoniae, L. pneumophila, Mycobacterium tuberculosis, C. pneumoniae, M. pneumoniae |
| 2008 | MX-PCR | Enzyme hybridization or electronic microarray detection | P1 gene (299) | ND | Various bacterial and viral species, bacterial dilutions, spiked clinical specimens, clinical specimens from carriage study, re-analysis of samples with discrepant results. Pathogens targeted: influenza virus A, influenza virus B, RSV A and B, M. pneumoniae, C. pneumoniae, L. pneumophila, L. micdadei, B. pertussis, S. aureus, S. pneumoniae |

A-test: passive agglutination-test; MX-PCR: multiplex PCR; NASBA: nucleic acid sequence-based amplification; NPA: nasopharyngeal aspirate; NS: not specified; Pneumoplex (GenProbe Prodesse Inc., Waukesha, WI, USA); ResPlex (Qiagen GmbH, Valencia, CA, USA); M. pneumoniae OligoDetect PCR kit (Millipore/Chemicon, Eugene, OR, USA)
specimens. The analytical sensitivity of this assay was between 1–5 CFU, whereas it was between 5–50 CFU for the other two assays. However, the authors concluded that the inclusion of a second PCR assay may provide an increased level of confidence for the reporting of results. Dumke and Jacobs [52] compared under standardized conditions the performance of two commercial PCR assays (Artus RepMp1 [QIAGEN GmbH, Hilden, Germany] and the Venor Mp-QP M. pneumoniae kit [Minerva Biolabs GmbH, Berlin, Germany] and three in-house PCR assays for the detection of M. pneumoniae on the LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). All five procedures were able to demonstrate M. pneumoniae DNA in a concentration comparable to 1 CFU/µl, but the differences in the mean crossing points between the tested procedures (up to 4.6) caused differences of the calculated mean concentration of the genome equivalents by a factor of up to 20.

Multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from >2 centers independently are likely to provide important insights into the performance of new assays. To date, only two such studies describing multicenter comparisons of the performance of various NAATs for the detection of M. pneumoniae in respiratory specimens have been published, and both studies revealed significant variations of test performance from laboratory to laboratory [2, 53]. Ursi et al. collected a panel of 78 respiratory samples from 43 patients which were analyzed in three different centers for the presence of M. pneumoniae DNA by different PCR assays [53]. Nucleic acids were extracted at one site and subsequently amplified in three centers. Loens et al. [2] used spiked respiratory specimens to compare the performance of several NAATs being used by 18 laboratories, each with their own extraction and amplification protocols. Both of these studies revealed significant intercenter discordance of detection rates, using different or even the same tests, despite the fact that the laboratories participating were very experienced with the different or even the same tests, despite the fact that the laboratories participating were very experienced with the use of PCR assays. In the spring of 2008, a pilot panel for the molecular diagnosis of M. pneumoniae was produced by Quality Control for Molecular Diagnostics (QCMD). An external quality assessment (EQA) panel consisting of a total of 13 samples in bronchoalveolar lavage (BAL) or transport medium were prepared to assess the proficiency of laboratories in the correct detection of Chlamydia pneumoniae and Mycoplasma pneumoniae by NAATs (six samples containing various concentrations [4.9–490 inclusion forming units (IFU)/ml] of C. pneumoniae, five samples containing various concentrations [20–5,000 color changing units (CCU)/ml] of M. pneumoniae, and two samples negative for both) [54]. Seventy-nine laboratories from 18 countries participated in this EQA study. Sixty-seven datasets were obtained for M. pneumoniae (n = 5 conventional commercial, n = 10 conventional in-house, n = 4 real-time commercial, n = 46 real-time in-house, n = 2 strand displacement amplification [SDA]). For the total panel, correct results per sample varied between 53.7 and 95.5% for M. pneumoniae.

Respiratory viruses and other so-called “atypical bacteria” are all responsible for RTIs that may produce clinically similar manifestations. In order to reduce costs and hands-on time, multiplex nucleic acid amplification techniques (MX-NAATs) have been developed (Table 4). Originally only two or three organisms were targeted in one assay. Currently, some assays detect up to 22 targets [55]. However, comparison between monoplex and multiplex assays has been rarely performed. Findings and conclusions result frequently in contradictory and conflicting data concerning the sensitivity and specificity of the MX-NAATs compared to the monoplex NAAT. Owing to the complexity of the variables in a multiplex PCR, including different combinations of primer concentrations, magnesium ion concentrations, and annealing temperatures, this is not unexpected. The results of MX-NAATs on proficiency panels [2] seem to confirm that multiplex assays are somewhat less sensitive than monoplex assays, but until the number of organisms present in the clinic specimens of diseased individuals is known, it is impossible to state whether the degree of sensitivity attained is clinically acceptable.

It has been proposed that industry-produced assays in kit form may enable standardization. The Pneumoplex assay (Prodesse Inc.) (Table 4) was reported to have 100% sensitivity (when the sample contained 5 CFU/ml of M. pneumoniae) and 96% specificity for the detection of M. pneumoniae in spiked specimens [56]. The sensitivity of the Chlamylege assay (Argene Inc.) (Table 4) was 5.10−2 CCU per reaction tube for M. pneumoniae [57]. A cohort of 154 clinical samples from patients with documented respiratory infections was analyzed by the same kit, including two samples from patients with C. pneumoniae infection, nine samples from patients with M. pneumoniae infection, 19 samples from patients with Legionella species infection, and 114 samples that tested negative for the three pathogens. All of the positive specimens were correctly detected and identified by the Chlamylege kit, and no false-positive result was observed with the negative samples. The kit was then evaluated in a pediatric prospective study that included 220 endotracheal aspirates, and the results were compared with those obtained by three monoplex in-house PCR assays. Six specimens were found to be positive for M. pneumoniae by using both strategies. The Chlamylege kit detected two additional samples positive for M. pneumoniae. A comparative analysis of the limits of detection of the ResPlex I assay (Table 4) and real-time single PCR assays

© Springer
demonstrated that the ResPlex I assay is 10-fold less sensitive in detecting *M. pneumoniae* [58]. Furthermore, the ResPlex I assay was performed on 49 nasopharyngeal swab specimens known to be positive by real-time PCR for three pathogens (*C. pneumoniae*, *M. pneumoniae*, and *S. pneumoniae*) and detected 50, 59, and 81% of the *C. pneumoniae*-*, M. pneumoniae*- and *S. pneumoniae*-positive samples, respectively. However, since the calculation of the sensitivities of the industry-produced multiplex assays was mainly dependent on the DNA copy number, further evaluation and standardization using an extended number of clinical specimens that may have a low load of the organism are needed.

There is also more and more a trend of adapting commercially available (e.g., MicroSeq Mycoplasma, Applied Biosystems) or in-house PCR assays for screening cell cultures for the presence of Mollicutes to respiratory specimens for the specific or generic detection of *M. pneumoniae* [59, 60]. These assays need to be extensively validated in terms of sensitivity and specificity as well before they can be applied to clinical respiratory specimens.

Ideally, a newly proposed NAAT assay should be validated by comparison with a sensitive culture system and at least one validated PCR or another NAAT assay that targets a different gene or a different sequence of the same gene.

Conventional manual nucleic acid extraction for the isolation of pathogen DNA or RNA from clinical samples is the most labor-intensive and critical part in current nucleic acid diagnostic assays. Automated nucleic acid extraction systems with high flexibilities in the type and numbers of samples to be handled, and with a wide range of sample input and elution volumes and short turnaround time will improve the application of NAATs to clinical services. Data from the literature indicate that the sensitivity of an NAAT after nucleic acid extraction with an automated system is similar to or better than the sensitivity after manual nucleic acid extraction. When the easyMAG nucleic acid extractor (bioMérieux) was applied retrospectively to clinical specimens, better amplification results were obtained for *M. pneumoniae* and *C. pneumoniae* detection compared with manual methods such as the Qiagen blood mini kit and the NucliSens miniMAG platform [61, 62]. This and other automated nucleic acid extraction instruments need to be further evaluated.

### Antibiotic resistance

Since in 2001 a report was published describing the first macrolide-resistant *M. pneumoniae* strain possessing a 23S rRNA gene mutation [63], other reports followed [64–67]. Although most macrolide-resistant strains were detected in Japan so far, the first macrolide-resistant *M. pneumoniae* strains in Europe were reported recently in France [68]. Since the impact of macrolide resistance on the outcome of the infections is not clear so far, measures need to be taken to identify these strains and PCR assays have been developed to detect some of these mutations [64, 69]. Both assays target the V-domain of the 23S rRNA gene; the presence of point mutations in the amplicons is detected by using restriction fragment length polymorphism (RFLP) [64] or high-resolution melt curve analysis [69].

### Conclusions and future directions

During recent years, significant progress has been made in the microbiological diagnosis of *Mycoplasma pneumoniae* respiratory tract infections (RTIs). Despite these many efforts, much is still unknown about the role of *M. pneumoniae* in respiratory and other infections. Most *Mycoplasma* infections never have a microbiological diagnosis because rapid, sensitive, and specific methods for its direct detection are not readily available in physician offices or hospital laboratories.

Significant limitations continue to surround the accurate and reliable serological diagnosis of *M. pneumoniae* infection. These include the wide variation of the methods and diagnostic criteria used across studies, which results in the subsequent emergence of data that remain incomparable and often controversial because of discordant and, at times, incorrect methodologies used.

Numerous in-house PCR assays to detect *M. pneumoniae* have been developed. Proper validation and standardization are still often lacking, and quality control studies have revealed frequent deficiencies, resulting in both false-negative and false-positive results [2, 54]. Consequently, all newly developed tests must be submitted to extensive validation before their introduction in the molecular diagnostic laboratory. Validation must be performed at several levels, including sample preparation, amplification, and detection. Since respiratory samples often contain substances inhibiting amplification, special attention should be paid to the efficiency of the reaction with these samples. Once a test is validated, it should be further evaluated in proficiency testing programs. Whereas quality control is an essential part of quality assurance in molecular diagnostics, proficiency panels for the detection of *M. pneumoniae* are not readily available. They are urgently needed to allow meaningful comparisons between the results obtained in different laboratories.

In conclusion, the following standards should be followed by all laboratories when validating new tests for the detection of *M. pneumoniae*: (i) having the ability to apply a second PCR at another target to at least some cases in epidemic situations; (ii) performing proficiency testing regularly in a blind fashion to ensure proper test and
personnel performance; and (iii) incorporating hierarchical acceptance criteria monitoring for test failures, including positive and negative controls, re-evaluating multiple consecutive positive specimens, and confirming that positive specimens were collected from persons meeting the clinical case definition. Furthermore, multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from >2 centers independently are likely to provide important insights into the performance of new assays.

Given the high sensitivity and specificity of nucleic acid amplification techniques (NAATs), NAATs are the preferred diagnostic procedures for the diagnosis of *M. pneumoniae* infections, provided that the quality of the procedures is controlled. Additional prospective multicenter studies on large numbers of patients with respiratory signs and symptoms, including hospitalized and non-hospitalized patients, are necessary to extend our knowledge on the epidemiology of *M. pneumoniae*.

Acknowledgments Katherine Loens is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of European Union’s Sixth Framework Programme (FP6), contract number: LSHM-CT-2005-518226, GRACE.

References

1. Loens K, Ursi D, Goossens H, leven M (2003) Molecular diagnosis of *Mycoplasma pneumoniae* respiratory tract infections. J Clin Microbiol 41:4915–4923
2. Loens K, Beck T, Ursi D, Pattyn S, Goossens H, leven M (2006) Two quality control exercises involving nucleic acid amplification methods for detection of *Mycoplasma pneumoniae* and *Chlamydo-philina pneumoniae* and carried out 2 years apart (in 2002 and 2004). J Clin Microbiol 44:899–908
3. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarnier J, Hammerschlag MR, Jackson LA, Kuo CC, Maass M, Messmer TO, Talkington DF, Tondella ML, Zaki SR (2001) Standardizing *Chlamydia pneumoniae* assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 33:492–503
4. Foy HM (1993) Infections caused by *Mycoplasma pneumoniae* and possible carrier state in different populations of patients. Clin Infect Dis 17(Suppl 1):S37–S46
5. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, Gaydos CA, Joseph JM, Gopalan R, Moore RD (1995) Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 152:1309–1315
6. van Kuppeveld FJ, Johansson KE, Galama JM, Kissing J, Bölks G, Hjelm E, van der Logt JT, Melchers WJ (1994) 16S rRNA based polymerase chain reaction compared with culture and serological methods for diagnosis of *Mycoplasma pneumoniae* infection. Eur J Clin Microbiol Infect Dis 13:401–405
7. Nagalingam NA, Adesiyun AA, Swanston WH, Bartholomew M (2004) Prevalence of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in pneumonia patients in four major hospitals in Trinidad. New Microbiol 27:345–351
8. Oosterheert JJ, van Loon AM, Schuurman R, Hoepelman AI, Hak E, Thijssen S, Nossent G, Schneider MM, Hastinx WM, Bonten MJ (2005) Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 41:1438–1444
9. Don M, Fasoli L, Paldanius M, Vainionpää R, Kleemola M, Räty R, Leinonen M, Korppi M, Tenore A, Canciani M (2005) Aetiology of community-acquired pneumonia: serological results of a paediatric survey. Scand J Infect Dis 37:806–812
10. Lehtinen P, Jartti T, Virkki R, Vuorinen T, Leinonen M, Peltola V, Ruohola A, Russkanen O (2006) Bacterial coinfections in children with viral wheezing. Eur J Clin Microbiol Infect Dis 25:463–469
11. Shenoy GD, Upadhyaya SA, Rao SP, Shobha KL (2005) *Mycoplasma pneumoniae* infection in children with acute respiratory infection. J Trop Pediatr 51:232–235
12. Grutteke P, Glas AS, Dierdorf M, Vreeve WB, Pilon JW, Bruisten SM (2004) Practical implementation of a multiplex PCR for acute respiratory tract infections in children. J Clin Microbiol 42:5596–5603
13. Liu G, Talkington DF, Fields BS, Levine OS, Yang Y, Tondella ML (2005) *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* in young children from China with community-acquired pneumonia. Diagn Microbiol Infect Dis 52:7–14
14. Gaillat J, Flahault A, deBarbeyrac B, Orfila J, Portier H, Ducroix JP, Bébéar C, Mayaud C (2005) Community epidemiology of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* in LRTI in France over 29 months. Eur J Epidemiol 20:643–651
15. Maltezou HC, La-Scola B, Astra H, Constantopoulos I, Vlahou V, Kafetzis DA, Constantopoulos AG, Raoult D (2004) *Mycoplasma pneumoniae* and *Legionella pneumophila* in community-acquired lower respiratory tract infections among hospitalized children: diagnosis by real time PCR. Scand J Infect Dis 36:639–642
16. Schneeberger PM, Dorigo-Zetsma JW, van der Zee A, van Bon M, van Opstal JL (2004) Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection. Scand J Infect Dis 36:269–273
17. Sidal M, Kilic A, Unuvar E, Oguz F, Onel M, Agacidian A, Aydin D, Koksalan K, Bekä H (2007) Frequency of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* infections in children. J Trop Pediatr 53:225–231
18. Strålin K, Törnqvist E, Kaltoft MS, Olcén P, Holmberg H (2006) ETologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. J Clin Microbiol 44:643–645
19. van de Garde EM, Endeman H, van Hemert RN, Voorn GP, Deneer VH, Leutkens HG, van den Bosch JM, Biesma DH (2008) Prior outpatient antibiotic use as predictor for microbial aetiology of community-acquired pneumonia: hospital-based study. Eur J Clin Pharmacol 64:405–410
20. Yamazaki T, Narita M, Sasaki N, Kenri T, Arakawa Y, Sasaki T (2007) *Mycoplasma pneumoniae* and *Legionella pneumophila* in respiratory specimens from patients with community-acquired pneumonia: hospital-based study. J Clin Microbiol 45:273–279
21. Kogan R, Martinez MA, Rubilar L, Payá E, Quevedo I, Puppo H, Girardi G, Castro-Rodriguez JA (2003) Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr Pulmonol 35:91–98
22. Loens K, Beck T, Ursi D, Overdijk M, Sillekens P, Goossens H, leven M (2008) Evaluation of different nucleic acid amplification techniques for the detection of *M. pneumoniae*, *C. pneumoniae* and *Legionella* spp. in respiratory specimens from patients with community-acquired pneumonia. J Microbiol Methods 73:257–262

Eur J Clin Microbiol Infect Dis (2010) 29:1055–1069
56. Khanna M, Fan J, Pehler-Harrington K, Waters C, Douglass P, Stallcock J, Kuhl S, Henrickson KJ (2005) The pneumoplex assays, a multiplex PCR–enzyme hybridization assay that allows simultaneous detection of five organisms, Mycoplasma pneumoniae, Chlamydia (Chlamydiophila) pneumoniae, Legionella pneumophila, Legionella micdadei, and Bordetella pertussis, and its real-time counterpart. J Clin Microbiol 43:565–571

57. Ginevra C, Baranger C, Ros A, Mory O, Stephan JL, Fremyth F, Joannis M, Pozzetto B, Grattard F (2005) Development and evaluation of Chlamylyge, a new commercial test allowing simultaneous detection and identification of Legionella, Chlamydiophila pneumoniae, and Mycoplasma pneumoniae in clinical respiratory specimens by multiplex PCR. J Clin Microbiol 43:3247–3254

58. Benson R, Tondella ML, Bhatnagar J, Carvalho Mda G, Sampson JS, Tarkington DF, Whitney AM, Mohsrehti E, McGee L, Carlone G, McClell V, Guermer J, Zaki S, Dejsri S, Cronin K, Han J, Fields BS (2008) Development and evaluation of a novel multiplex PCR technology for molecular differential detection of bacterial respiratory disease pathogens. J Clin Microbiol 46:2074–2077

59. Störmer M, Vollmer T, Henrich B, Kleesiek K, Dreier J (2009) Broad-range real-time PCR assay for the rapid identification of cell-line contaminants and clinically important mollicute species. Int J Med Microbiol 299:291–300

60. Wang H, Kong F, Jefts P, James G, Gilbert GL (2004) Simultaneous detection and identification of common cell culture contaminant and pathogenic mollicutes strains by reverse line blot hybridization. Appl Environ Microbiol 70:1483–1486

61. Loens K, Bergs K, Ursi D, Goossens H, Ieven M (2007) Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens. J Clin Microbiol 45:421–425

62. Loens K, Ursi D, Goossens H, Ieven M (2008) Evaluation of the NucliSens miniMAG RNA extraction and real-time NASBA applications for the detection of Mycoplasma pneumoniae and Chlamydiophila pneumoniae in throat swabs. J Microbiol Methods 72:217–219

63. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki Y, Arakawa Y, Sasaki T (2001) Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 45:617–620

64. Matsuoka M, Narita M, Okazaki N, Ohyama H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shinant M, Arakawa Y, Sasaki T (2004) Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 48:4624–4630

65. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura S, Takayanagi R, Andoh T, Matsuzaka M, Kenri T, Arakawa Y, Sasaki T (2006) Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 52:348–350

66. Suzuki T, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T (2006) First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesion gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol 45:3534–3539

67. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM (2008) Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 52:3542–3549

68. Morozumi M, Hasegawa K, Chiba N, Iwata S, Kawamura N, Kuroki H, Tajima T, Ubukata K (2004) Application of PCR for Mycoplasma pneumoniae detection in children with community-acquired pneumonia. J Infect Chemother 10:274–279

69. Templeton KE, Schelling SA, Graffelman AW, Van Schie JM, Crieaard JW, Sillekens P, van den Broek PJ, Goossens H, Beersma MF, Claas EC (2003) Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J Clin Microbiol 41:4366–4371

70. Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H (1996) Detection of Mycoplasma pneumoniae by two polymerase chain reaction assays and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis 173:1445–1452

71. Loens K, Ieven M, Ursi D, Beck T, Overdijk M, Sillekens P, Goossens H (2003) Detection of Mycoplasma pneumoniae by real-time nucleic acid sequence-based amplification. J Clin Microbiol 41:4448–4450

72. Roth SB, Jalava J, Ruuskapanen O, Ruohola A, Nikiari S (2004) Use of an oligonucleotide array for laboratory diagnosis of bacteria responsible for acute upper respiratory infections. J Clin Microbiol 42:4268–4274

73. Raggam RB, Leitner E, Berg J, Müblbauer G, Mart M, Kessler HH (2005) Single-run, parallel detection of DNA from three pneumonia-producing bacteria by real-time polymerase chain reaction. J Mol Diagn 7:133–138

74. Saito R, Misawa Y, Moriya K, Koike K, Ubukata K, Okamura N (2005) Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of Mycoplasma pneumoniae. J Med Microbiol 54:1037–1041

75. Ieven M, Dirven K, Loens K, Ieven M, Goossens H (2003) Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control. J Microbiol Methods 55:149–153

76. Morozumi M, Nakayama E, Iwata S, Aoki Y, Hasegawa K, Kobayashi R, Chiba N, Tajima T, Ubukata K (2006) Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time PCR with pathogen-specific molecular beacon probes. J Clin Microbiol 44:1440–1446

77. Pitcher D, Chalker VJ, Sheppard C, George RC, Harrison TG (2006) Real-time detection of Mycoplasma pneumoniae in respiratory samples with an internal processing control. J Med Microbiol 55:149–155

78. Di Marco E, Cangioli G, Filippetti M, Melioli G, Biasoni R (2007) Development and clinical validation of a real-time PCR using a uni-molecular Scorpion-based probe for the detection of Mycoplasma pneumoniae in clinical isolates. New Microbiol 30:415–421

79. Kong F, Gordon S, Gilbert GL (2000) Rapid-cycle PCR for detection and typing of Mycoplasma pneumoniae in clinical specimens. J Clin Microbiol 38:4256–4259

80. Sharma S, Brousseau R, Kasatiya S (1998) Detection and confirmation of Mycoplasma pneumoniae in urogenital specimens by PCR. J Clin Microbiol 36:277–280

81. Dumke R, Schurwanz N, Lenz M, Schuppler M, Lück C, Jacobs E (2007) Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. J Clin Microbiol 45:2726–2730

82. Miyashita N, Saito A, Kohno S, Yamaguchi K, Watanabe A, Okada H, Kazuyama Y, Matsushima T (2004) Multiplex PCR for the...
simultaneous detection of *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella pneumophila* in community-acquired pneumonia. Respir Med 98:542–550
85. Briese T, Palacios G, Kokoris M, Jabado O, Liu Z, Renwick N, Kapoor V, Casas I, Pozo F, Limberger R, Perez-Brena P, Ju J, Lipkin WI (2005) Diagnostic system for rapid and sensitive differential detection of pathogens. Emerg Infect Dis 11:310–313
86. de Barbeyrac B, Bernet-Poggi C, Fébrer F, Renaudin H, Dupon M, Bébéar C (1993) Detection of *Mycoplasma pneumoniae* and *Mycoplasma genitalium* in clinical samples by polymerase chain reaction. Clin Infect Dis 17(Suppl 1):S83–S89
87. McDonough EA, Barrozo CP, Russell KL, Metzgar D (2005) A multiplex PCR for detection of *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, *Legionella pneumophila*, and *Bordetella pertussis* in clinical specimens. Mol Cell Probes 19:314–322
88. Strålin K, Bäckman A, Holmberg H, Fredlund H, Olcén P (2005) Design of a multiplex PCR for *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* to be used on sputum samples. APMIS 113:99–111
89. Geertsen R, Kaeppeli F, Sterk-Kuzmanovic N, Andrasevic S, Anic-Milic T, Dobec M (2007) A multiplex PCR assay for the detection of respiratory bacteria in nasopharyngeal smears from children with acute respiratory disease. Scand J Infect Dis 39:769–774
90. Lam WY, Yeung AC, Tang JW, Ip M, Chan EW, Hui M, Chan PK (2007) Rapid multiplex nested PCR for detection of respiratory viruses. J Clin Microbiol 45:3631–3640
91. Lodes MJ, Suciu D, Wilmoth JL, Ross M, Munro S, Dix K, Bernards K, Stöver AG, Quintana M, Iihoshi N, Lyon WI, Danley DL, McShea A (2007) Identification of upper respiratory tract pathogens using electrochemical detection on an oligonucleotide microarray. PLoS ONE 2:e924
92. Gullsby K, Storm M, Bondeson K (2008) Simultaneous detection of *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae* by use of molecular beacons in a duplex real-time PCR. J Clin Microbiol 46:727–731
93. van Kuppeveld FJ, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ (1992) Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl Environ Microbiol 58:2606–2615
94. Loens K, Beck T, Ursi D, Overdijk M, Sillekens P, Goossens H, Leven M (2008) Development of real-time multiplex nucleic acid sequence-based amplification for detection of *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, and *Legionella* spp. in respiratory specimens. J Clin Microbiol 46:185–191
95. Wang Y, Kong F, Yang Y, Gilbert GL (2008) A multiplex PCR-based reverse line blot hybridization (mPCR/RLB) assay for detection of bacterial respiratory pathogens in children with pneumonia. Pediatr Pulmonol 43:150–159
96. Kumar S, Wang L, Fan J, Kraft A, Bose ME, Tiwari S, Van Dyke M, Haigis R, Luo T, Ghosh M, Tang H, Haghnia M, Mather EL, Weisburg WG, Henrickson KJ (2008) Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray) detection. J Clin Microbiol 46:3063–3072